Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 18, 2023 | Press Releases

— PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — — Stable systemic immune induction was observed in the 750mg cohort, with CD8+ T cells and NK cell activation significantly increasing from...

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 14, 2023 | Press Releases

SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...

Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2022 | Press Releases

SAN DIEGO, April 8, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...

Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 28, 2022 | Press Releases

SAN DIEGO, March 28, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papillomavirus-driven pre-cancerous cervical lesions, today announced that...

Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)

Mar 21, 2022 | Press Releases

— PRTX007 exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV) — — Findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to support...

Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Mar 10, 2022 | Press Releases

SAN DIEGO, March 10, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...